SAN JOSE, Calif., Nov. 28, 2017 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS), a company using the power of the immune system to diagnose and treat cancer, today announced that the United States Patent and Trademark Office ("USPTO") has issued a...
On November 13, ITUS Corporation announced that they had licensed a cancer therapy from the Wistar Institute, a Philadelphia based biomedical research organization. In doing so, ITUS has suddenly become a player in the hottest space in the medical industry,...
Tailwinds' Take: this is a big deal for ITUS as Moffitt is one of the preeminent cancer research centers in the US and their agreeing to collaborate on ITUS' CAR-T therapy is a very nice endorsement of this early-stage...
In the twenty-first century, AI techniques have experienced a massive surge in interest following concurrent advances in computer power, large amounts of data, and theoretical understanding. Companies are focused on it, Google has rebuilt their software around it, and Mark Zuckerberg...
Tailwinds' Take: While there remains a lot of work to be done, the pre-clinical work to date has yielded excellent results. Progress in attacking solid tumors with a CAR-T therapy would be first of its kind and very big...
A recent addition to the Tailwinds Select Portfolio, ITUS Corporation is a compelling young biotech startup located in San Jose. Led by Dr. Amit Kumar, a well-regarded scientist and business leader who is a board member of the American...
In the 1st of this two-part series, we examine ITUS’ work with its lead product, Cchek, a revolutionary cancer diagnostic. In part 2 we will look at their novel CAR-T solid tumor opportunity. On Thursday afternoon, November 2, we added...
SAN JOSE, CA -- (Marketwired) -- 10/27/17 -- ITUS Corporation (NASDAQ: ITUS) today announced that it has satisfied all obligations under its secured debenture by paying the creditor the outstanding principal and interest in cash ahead of its due date. As...
SAN JOSE, CA -- (Marketwired) -- 09/21/17 -- ITUS Corporation (NASDAQ: ITUS) today provides a corporate update before its Annual Meeting of Stockholders to be held on September 22, 2017. ITUS's wholly owned subsidiary Anixa Diagnostics, recently renewed its research agreement with...
SAN JOSE, CA -- (Marketwired) -- 09/18/17 -- ITUS Corporation (NASDAQ: ITUS), today announced that the United States Patent and Trademark Office ("USPTO") has issued U.S. Patent 9,739,783, to inventors Dr. Amit Kumar, Chief Executive Officer, and John Roop, VP...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.